Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow REVIVA PHARMACEUTICALS HOLDINGS, INC.

Get SEC filing alerts via email and in your feed for REVIVA PHARMACEUTICALS HOLDINGS, INC.

RVPH RVPHW

REVIVA PHARMACEUTICALS HOLDINGS, INC.

About REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals develops novel therapeutics targeting central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes drug candidates like brilaroxazine, a receptor modulator for schizophrenia, bipolar disorder, depression, and respiratory conditions. Using proprietary chemistry and chemical genomics, the company focuses on clinical development and potential commercialization of treatments with broad efficacy, safety, and tolerability profiles for unmet medical needs in global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from REVIVA PHARMACEUTICALS HOLDINGS, INC.

1
1
REVIVA PHARMACEUTICALS HOLDINGS, INC. Reviva Pharmaceuticals Reports 50% Reduction in Net Loss for Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
REVIVA PHARMACEUTICALS HOLDINGS, INC. Reviva Pharmaceuticals Reports $19.9M Net Loss for Fiscal Year 2025, Focuses on Brilaroxazine Development

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
REVIVA PHARMACEUTICALS HOLDINGS, INC. Reviva Pharmaceuticals Reports Reduced Net Losses and Strategic Funding Developments for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
REVIVA PHARMACEUTICALS HOLDINGS, INC. Reviva Pharmaceuticals Reports Decreased Net Losses and Raises $10 Million in Public Offering

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
REVIVA PHARMACEUTICALS HOLDINGS, INC. Reviva Pharmaceuticals Reports $6.4 Million Net Loss in Q1 2025, Seeks Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
REVIVA PHARMACEUTICALS HOLDINGS, INC. Reviva Pharmaceuticals Reports $29.9M Net Loss, Advances Brilaroxazine Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
REVIVA PHARMACEUTICALS HOLDINGS, INC. Reviva Pharmaceuticals Reports Decline in Cash and Cash Equivalents, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments